Liver cirrhosis in Japan:Future global trends in the era of progressive antiviral therapy  

作　　者：Hirayuki Enomoto Tomoyuki Takashima Takashi Nishimura Nobuhiro Aizawa Naoto Ikeda Yukihisa Yuri Mamiko Okamoto Kohei Yoshihara Ryota Yoshioka Shoki Kawata Shogo Ota Ryota Nakano Hideyuki Shiomi Hiroko Iijima 

机构地区：[1]Department of Internal Medicine,Division of Hepatobiliary and Pancreatic Disease,Hyogo Medical University,Hyogo,Japan

出　　处：《Portal Hypertension & Cirrhosis》2022年第3期178-183,共6页门静脉高压与肝硬化（英文）

摘　　要：In Japan,viral hepatitis is the main cause of chronic liver diseases,including liver cirrhosis.Due to the availability of highly effective antiviral drugs in combination with antihepatitis measures,Japan has become one of the most successful countries in the world with regard to hepatitis virus elimination.In Japan,there are many elderly patients who have been infected with hepatitis C virus for a long time,and antihepatitis measures have been in place since the 2000s.Thus,the medical situation in Japan is expected to reflect the future situation in other countries where hepatitis countermeasures have been recently initiated and the infected population is aging.Our nationwide survey clarified the changes in the etiologies of liver cirrhosis in Japan.Although viral hepatitis remains a major cause of liver cirrhosis in Japan,nonviral cirrhosis is suggested to increasingly contribute to the etiologies of liver cirrhosis,as opposed to viral hepatitis‐related liver cirrhosis.The changing etiology of liver cirrhosis in Japan may help to predict future global trends in chronic liver diseases.

关 键 词：antihepatitis measures antiviral drugs ETIOLOGY liver cirrhosis viral hepatitis 

分 类 号：R57[医药卫生—消化系统]